Table 1.
Overview of microarray-based genome-wide expression analysis in the in vivo trimethyltin (TMT)-induced models of neurodegeneration.
| Model animal (No. of samples per experimental group) | Age at treatment | Rodent strain – Animal gender a | TMT dosage (administration route) | Hippocampal tissue specimen | Tested time points (post-TMT treatment) | Reference |
|---|---|---|---|---|---|---|
| Mouse (n = 3) | Adult | B6, 129 Nfkb1 tmlBal B6,129 2/J – F/M | p-50 null: 2.0 mg/kg; Non transgenic: 2.25 mg/kg | Whole hippocampus | 7 days | [23] |
| Mouse (n = 10) | P21 | CD-1 – M | 3 mg/Kg (i.p.) | Microdissected DG and CA | 6–18 h | [24] |
| Mouse (n = 3) | P120 | CD-1 – M | 2.4 mg/Kg (i.p.) | Whole hippocampus | 24 h | [15] |
| Mouse (n = 3) | P21 1 year | CD-1 – M | 2.3 mg/Kg (i.p.) | Microdissected SGZ | 48 h | [10] |
| Rat (n = 3) | 6 weeks | Sprague–Dawley – M | 9 mg/Kg (oral) | Whole hippocampus | 2–5 days | [25] |
| Rat (n = 3) | 6 weeks | Long –Evans – F/M | 8.0 mg/Kg (i.p.) | Whole hippocampus | 3–5 days | [26] |
a
F: female; M: male; F/M: both sexes.